Dr. Kyeong Lee, a former post-doctoral fellow in the Burke group, and now a pharmaceutical professor at Dongguk University in South Korea, in collaboration with researchers at KRIBB has developed a new anti-cancer drug candidate that regulates HIF-1α. A technology transfer agreement was signed with Ildong Pharmaceutical Co. Ltd in the fall of 2011 for further development into a broad-spectrum anticancer drug. In addition, Dr. Lee was chosen by the National Research Foundation of Korea as the lead researcher for the Open Translational Center for Innovative Drug (OTRCID). The focus of the OTRCID is to discover global level preclinical candidates to be used for further development. The Dongguk research team is expected to develop global anti-cancer drug candidates over the next 6 years.
For the full story, please look for the newsclippings (article #s 387169 and 11510362) on
the Dongguk University website at www.dongguk.edu/mbs/en/index.jsp